GlassScriptPhysician profile
Monique Iris Allman
NPI 1659605723
$11,166.83
in general payments reported to CMS, 2019-2025
31 companies · $2,034 in 2025
The $2,034 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $880 · 2022: $1,282 · 2023: $5,001 · 2024: $1,968 · 2025: $2,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,763 · Consulting Fee: $2,375 · Travel and Lodging: $772 · Education: $94.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,763.13 |
| Consulting Fee | $2,375.00 |
| Travel and Lodging | $771.66 |
| Education | $94.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,346.72 | 2023-2024 | Xolair |
| Astrazeneca Pharmaceuticals LP | $2,490.59 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,196.25 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Optinose US, INC. | $565.41 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $506.25 | 2022-2025 | Cuvitru, Takhzyro, Eohilia |
| Pfizer INC. | $253.82 | 2021-2025 | |
| Genzyme Corporation | $253.71 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $217.47 | 2021-2024 | |
| Pharming Healthcare, INC. | $209.09 | 2021-2025 | Ruconest |
| Octapharma USA, INC. | $176.55 | 2024 | Cutaquig |
| Ars Pharmaceuticals Operations, INC. | $172.52 | 2025 | Neffy |
| Grifols USA, LLC | $168.01 | 2021-2024 | Xembify |
| Incyte Corporation | $163.34 | 2022-2025 | |
| Amgen INC. | $146.34 | 2022-2025 | Tezspire |
| Csl Behring | $144.37 | 2023-2024 | Hizentra, Haegarda |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $134.92 | 2024 | Ayvakit |
| Kaleo, INC. | $133.73 | 2021-2024 | Auvi-Q |
| Eisai INC. | $124.26 | 2025 | |
| Jazz Pharmaceuticals INC. | $119.74 | 2021 | |
| Galderma Laboratories, L.P. | $115.94 | 2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $113.15 | 2022-2023 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $110.72 | 2024-2025 | |
| Novo Nordisk INC | $80.23 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $52.99 | 2025 | |
| Aroa Biosurgery Incorporated | $48.91 | 2024 | |
| Olympus America INC. | $27.48 | 2024 | |
| Merck Sharp & Dohme LLC | $21.30 | 2023 | |
| Hikma Pharmaceuticals USA | $19.12 | 2023 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $18.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.71 | 2021 | |
| Aimmune Therapeutics, INC. | $17.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Allman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.